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Abstract 
Engineered zinc finger proteins (ZFN) that bind specific DNA targets provide the foundation for a new class of technologies 
that promise significant gains in the development of novel therapeutics and molecular research tools. Individual zinc fingers 
have been developed in vitro to recognize many DNA triplets. When fused to the nonspecific DNA cleavage domain of the 
FOK1 restriction endonuclease, zinc fingers can direct double strand breaks to disrupt specific genes. Expanded triplet 
repeats have been identified as the genetic basis for a growing number of neurological disorders. Thus ZFN show promise for 
the treatment of monogenic disorders by promoting the knockout or correction of specific genes. 
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Introduction 
Neurons are postmitotic cells that must survive 
and function properly for the entire lifetime of the 
organism. Because they cannot be replaced and are 
subjected to high metabolic stress, mechanisms for 
coping with damaged molecules may be particularly 
important in these cells. Indeed, human 
neurodegenerative disorders, such as Alzheimer's and 
Parkinson's diseases, involve the abnormal 
accumulation of damaged proteins (1), and other 
syndromes, such as ataxia telangiectasia (AT), have 
been associated with defects in DNA-damage 
processing (2). Work done by El-Khamisy et al. (3) and 
a more recent study by Ahel et al. (4) have revealed 
that inefficient repair of DNA single-strand breaks 
(SSBs) can give rise to neurodegenerative disease, in 
particular, spinocerebellar ataxia with axonal 
neuropathy-1 (SCAN1) and ataxia oculomotor apraxia-
1 (AOA1), respectively. These data provide evidence 
that non-replicating, post-mitotic neurons are 
particularly sensitive to the accumulation of DNA SSBs. 
SSBs, one of the most common lesions formed in 
chromosomal DNA, are generated by the attack of 
reactive oxygen species (5) or as natural intermediates 
during certain DNA transactions, including repair and 
replication (6). In both instances, SSBs can harbor 
non-conventional 3′ or 5′ termini, such as phosphates, 
phosphoglycolates, or trapped polypeptides, which 
present obstacles to polymerization and ligation 
activities. To remove such obstructions, cells undergo 
SSB repair, a process related to the more classical 
base excision repair (BER) pathway (7). The SSB 
repair proteins excise terminal blocking groups, 
permitting gap-filling synthesis and sealing of the final 
nick in DNA. Zinc-finger nucleases (ZFN) link a DNA 
binding domain of the zinc-finger type to the nuclease 
domain of Fok I and enable the induction of double-
strand breaks (DSBs) at preselected genomic sites (4). 
DSBs closed by the error-prone, nonhomologous end-
joining (NHEJ) DNA repair pathway frequently exhibit 
nucleotide deletions and insertions at the cleavage site. 
This technology has been applied to introduce 
knockout mutations into the germ line of rats and 
zebrafish by the expression of ZFPs in early embryos 
that target coding sequences (8-11). On the other hand, 
DNA methylation contributes to cellular reprogramming 
and views on the function of CpG methylation are 
changing. In the early 1990s, it was already apparent 
that promoters with low CpG content did not show a 
clear relationship between methylation level and 
expression level (12,13). More recently, analysis of 
16,000 promoters in the human epigenome reveals 
that when CpG density is high there is a greater degree 
of methylation and this reasonably predicts gene 
expression. However, when CpG content is low, there 
is no clear relationship between methylation and 
expression (14). From the same data set, it is apparent 
that, whereas DNA methylation is sufficient to 
inactivate CpG-rich gene promoters, it is not necessary 
because many hypomethylated CpG-rich promoters are 
inactive. The associated chromatin structure is 
implicated as an additional regulatory variable in such 
circumstances and highlights the important interplay 
between DNA methylation and histone modifications. 
Additional proposed functions of CpG methylation 
include monoallelic expression, parasitic element 
silencing (12), or changes to the associated chromatin 
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(15). Moreover, some have suggested that many 
reported instances of a correlation between CpG 
methylation and expression patterns reflect a 
consequence of gene transcription on the epigenome 
and not vice versa. This review examines the 
importance of these epigenetic breakthroughs for 
treatment of neurodegenerative disorders by 
application of ZFPs. 
Highly efficient, targeted genome manipulation 
induced by ZFPs 
Gene targeting is a method to repair or inactivate 
any desired gene of interest. Gene targeting strategies 
use the introduction of a double-stranded break (DSB) 
into a genomic locus to enhance the efficiency of 
recombination with an exogenously introduced 
homologous DNA "repair template" (Figure 1) (16,17). 
DSBs can stimulate recombination efficiency several 
thousand-fold, approaching gene targeting frequencies 
as high as 50% (18-22). Early experiments utilized 
highly specific homing endonucleases, enzymes that 
bind and cleave extended DNA sequences, to 
introduce DSBs into specific genomic loci (17). To 
date, however, the use of homing endonucleases to 
enhance gene targeting has not been demonstrated at 
an actual endogenous gene locus.
  
 
Figure 1: Zif268 and DNA recognition residues 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The complex and multisystemic effects caused by 
defects in basic DNA-repair mechanisms are now well 
characterized. Research over many years has shown 
that neurodegenerative defects are often associated 
with repair syndromes, but it has been very difficult to 
establish the precise causative links between these 
processes. However, recent research on the 
neurodegenerative disorders ataxia with oculomotor 
apraxia 1 (AOA1) and spinocerebellar ataxia with 
axonal neuropathy 1 (SCAN1), which are caused by 
dysfunction of Aprataxin (APTX) and tyrosyl-DNA 
phosphodiesterase 1 (TDP1), respectively, sheds new 
light on the underlying basis of DNA repair-associated 
neurodegeneration (23-25). AOA1 and SCAN1 are 
autosomal recessive cerebellar ataxias, but in contrast 
to A-T, their phenotypes are very much restricted to the 
nervous system. Recent findings indicate that neuronal 
cell death in AOA1 and SCAN1 is primarily due to the 
specific proofreading roles that Aprataxin and TDP1 
play in the repair of DNA single-strand breaks (SSBs). 
This unprecedented correlation between molecular 
defect and neuron-specific impact may provide the 
missing link that allows us to begin to understand the 
relationship between neurodegeneration and defective 
DNA repair. 
 
The zinc-finger domain is required for aprataxin 
activity 
In retrospect, it is surprising that it took so long to 
uncover a role for Aprataxin as a DNA-specific 
adenylase. The presence of the N-terminal 
XRCC1/XRCC4-interacting FHA domain and the C-
terminal zinc finger (ZnF) domain provided significant 
clues to its actions on DNA. Recent studies have 
shown that Aprataxin binds both double- and single-
stranded DNA, in reactions dependent upon the ZnF 
motif (26). Moreover, the protein exhibits a high affinity 
for adenylated rather than nonadenylated DNA, and 
specific complex formation is again dependent upon 
the zinc-coordinating cysteines C319 and C322 (27). It 
is likely that Aprataxin uses its general DNA-binding 
capacity to scan the genome, such that the HIT and 
ZnF domains may then cooperate to form a high-
affinity complex that locks the enzyme onto adenylated 
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DNA lesions. Consistent with this proposal, the DNA 
adenylase activity is reduced 100-fold by mutation of 
the ZnF motif (27). The critical role that the ZnF plays 
in substrate recognition may explain why mutations 
that map to the C-terminal side of the catalytic HIT 
domain confer an AOA1 phenotype that is similar in 
severity to that caused by mutations within the HIT 
domain (28). 
 
Selective in vivo targeting of DNA methylation by 
Zinc finger proteins 
Mechanistically, one way DNA methylation can 
lead to transcriptional silencing is by decreasing the 
binding affinity of a transcriptional activator for its site 
(29). Although the mechanisms are still being 
elucidated there is a strong correlation between 
promoter methylation and gene silencing (30). Thus 
DNA methylation can be critical in defining the 
expression state of a gene. The design of multiple zinc-
finger with desired specificities is proving a versatile 
platform for targeting a variety of protein moieties to 
accessible sites in vivo as shown in Figure 2 (31,32). 
For instance, engineered zinc-finger proteins have 
been fused to the catalytic domain  of R-Fok1 
endonuclease to direct regions (33). Designed ZFP 
have also been used to target the catalytic domains of 
the histone methyltransferases G9A and SUV39H1 (34) 
as well as the VP16 activation domain (35). Leading to 
repression and activation, respectively, of expression of 
the human erythropoietin, vascular endothelial growth 
factor A and other mammanlian genes. 
 
 
Figure 2: Structure of six fingered TF-DNA complex 
 
 
 
 
 
 
 
 
 
 
 
 
The targeting of DMTases by zinc-finger proteins 
selecte to bind specific ZBS could provide an additional 
way to down- regulate the expression of desired genes. 
Moreover, since the DNA methylation state of a 
given promoter is maintained heritably through DNA 
replication by endogenous cellular mechanisms, an 
initial targeting event may be sufficient to establish 
stable silencing of improperly expressed genes. 
Therefore, heritable repression could also reduce the 
amount of treatment necessary to establish the proper 
regulation of a particular gene. In addition to providing a 
potentially powerful therapeutic tool, methylation-
mediated repression of specific- ally targeted genes 
could yield an alternative to transgenic knockouts for 
studying loss-of-function phenotypes. Silencing genes 
through DNA methylation would be particularly valuable 
in the case of essential genes where tissue-specific 
knockouts of function are needed. A ZFN directed at 
CAG repeat tracts might also prove useful as a 
therapeutic reagent for treatment of patients. 
Treatments that can promote the reduction of large 
CAG repeat tracts, or interrupt them, might form the 
basis for a future therapeutic approach designed to 
prevent or delay the onset of large stage neurological 
disorders caused by expanded CAG repeat tracts (36). 
 
Therapeutic uses of ZFN in neurodegenerative and 
related disorders 
Although ZFPs and ZFNs are still a recent area of 
research, there are some immediately applicable 
therapeutic opportunities that have arisen (37). For 
example, Sangamo biosciences have developed ZFPs 
fused to the VP16 transcriptional activation domain 
targeted to the VEGF-A promoter which is currently in 
Phase 2 trials for diabetic neuropathy and Amyotrophic 
Lateral Sclerosis (ALS). This drug, which involves 
direct injection of DNA encoding the ZFPs into the 
affected site, requires efficient uptake of the DNA and 
strong expression in the target tissues. In some 
diseases, it is not genomic DNA that is altered, but 
mitochondrial DNA. Neurogenic muscle weakness, 
ataxia, and retinitis pigmentosa (NARP) and maternally 
inherited Leigh's syndrome are caused by a single 
T8993G nucleotide alteration in mitochondrial DNA. A 
combination of adding a nuclear exclusion sequence 
and a mitochondrial targeting sequence was shown to 
be effective in localizing ZFNs to the mitochondria. 
However, the conventional heterodimeric ZFNs were 
unsuccessful at binding and/or cleaving the appropriate 
site in the mitochondrial genome. Therefore a model 
recently developed shows a novel single ZFN which 
expresses two Fok1 proteins separated by a flexible 
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linker, using ZFPs to direct this polypeptide to the 
T8993G mutation. When expressed in cells expressing 
copies of both the mutant and WT mitochondrial 
genome, this quasi-dimeric ZFN was able to selectively 
cleave the mutant copy leading to enrichment of the 
WT copy, which could be sufficient to reverse 
phenotypic consequences. ZNF219 is a member of the 
Krüppel-like zinc finger gene family and is a 77 kDa 
protein containing nine sets of C2H2 zinc finger 
structures (38). ZNF219 is widely expressed in many 
tissues, including the cerebellum, substantia nigra, 
hippocampus, and cerebral cortex (39, 40). ZNF219 
functions as a repressor of transcriptional activation in 
the promoter of the high-mobility group nucleosome 
binding domain 1 gene and competes for binding to its 
target sequence with members of the Sp1 family of 
transcriptional activators (36). In support of this view, in 
the luciferase assay, it was observed that no activation 
for constructs that contained either three or one 
ZNF219 binding sites. For constructs that contained 
two ZNF219 binding sites we observed an increase in 
luciferase activity. Therefore, the exact involvement of 
ZNF219 in the regulation of SNCA is somewhat 
unclear, and will require further characterization by 
deleting individual and multiple sites in the context of 
the full 1.9 kb construct. 
 
Conclusion 
It is becoming clear ever since the discovery of 
zinc finger proteins by Sir Aaron Klug that they could 
be critical for possible treatment of neurodegenerative 
disorders. The advances in understanding epigenetic 
modifications of DNA has opened new vistas for 
treating neurodegenerative disorders. Silencing genes 
through DNA methylation would be particularly 
valuable in the case of essential genes where tissue 
specific knock outs of function are needed. Moreover, 
the combination of strong zinc-finger binding and 
reduced methyltransferase activity gained from rational 
mutagenesis, has allowed us to target methylation 
predominantly to specific DNA sequences without 
incurring significant background methylation. These 
enzymes are fully functional in mammalian cells, where 
the targeted methylation pattern delivered is 
demonstrated to be inherited through successive cell 
divisions. In summary, the development of enzymes in 
which the dominant interaction with DNA is clearly 
driven by the zinc-finger component. The development 
of targeted Mtase enzymes and methodologies to 
analyse their function rapidly and within a relatively 
complex model system, together with the further 
characterization of their functional activity in vivo in 
mammalian cells, represents an important step towards 
the ultimate employment of this class of molecule in 
both research and therapeutic arenas.  
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